CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 211 · Search date 2026-07-11 · Methodology v0.6

Bergamot polyphenolic fraction,
does it really help with Improvement in LDL and triglycerides?

30-Second Summary
C
Evidence Grade C · 44 · Safety unknown
Bergamot has a lipid-improvement signal, but dependence on specific ingredients and manufacturers and study-quality limitations are substantial
What the
research shows
Bergamot extracts have reported reductions in LDL and triglycerides in several small RCTs and a meta-analysis, but extracts, doses, and populations differ, and many studies are low quality or manufacturer-linked. Outcomes are also blood-lipid surrogate markers, with no cardiovascular-event data, so the rating is C.
What the
ads claim
Advertising may present natural statin, cholesterol management, triglyceride reduction, and vascular protection together. Current human evidence consists of short-term blood-lipid changes from specific branded extracts, not evidence of drug substitution or cardiovascular-event prevention.
*

Useful facts when choosing a product

  • Marketed ingredients use different standardization methods and flavonoid contents, including BPF, phytosome, Bergavit, and Endoberg/Kalita.
  • Human trials used different doses, from about 150 mg/day standardized flavonoids to 350-1000 mg/day extract.
  • LDL and triglycerides are surrogate markers, and no long-term trial has evaluated reductions in myocardial infarction or stroke.
  • Short-term tolerability was generally good, but data on long-term safety and drug interactions are insufficient.
Gap Measurement · Verdict 211 · C 44
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Mollace 2019 RCT reported reductions in LDL and triglycerides with both standard BPF and a phospholipid formulation in 60 patients with type 2 diabetes and mixed hyperlipidemia, but Indena researchers participated. The Sadeghi-Dehsahraei 2022 meta-analysis of 14 trials calculated LDL -55.43 mg/dL and triglycerides -74.72 mg/dL but stated that results were inconsistent and higher-quality research was needed. The Fogacci 2023 RCT reported reductions of 17.7% in LDL and 16.6% in triglycerides in the high-dose arm among 90 adults with metabolic syndrome. The Spina 2024 RCT reported an 11.5% LDL reduction after four months in 64 adults with high cholesterol, but the trial data are owned by the sponsor and an ingredient-company employee was a coauthor.

02

Why this is classified as C (44)

Human RCTs and meta-analyses exist, so the rating is not D or ?. However, positive findings are concentrated in specific manufacturer ingredients, quality and heterogeneity problems are substantial, and only lipid surrogate markers were measured, resulting in C with 47 points.

Counterpoint. Specific standardized bergamot extracts have a signal of lowering LDL and triglycerides in populations with high cholesterol or metabolic syndrome. This assessment does not extend that signal to cardiovascular-event prevention or substitution for lipid-lowering medication.

Rejudgment record. New assessment — Several RCTs and a meta-analysis show positive lipid signals, but heterogeneity, low quality, manufacturer and formulation dependence are substantial, and only surrogate markers rather than clinical events were assessed

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Mollace V et al. 2019Randomized double-blind placebo-controlled trial60Indena R&D employees were coauthors; branded ingredientLDL, triglycerides, HDL, fasting glucose, and LDL particlesBoth standard BPF and BPF Phyto were reported to reduce LDL and triglycerides and increase HDL.Key
Sadeghi-Dehsahraei H et al. 2022Systematic review and meta-analysis14Academic institutionsTotal cholesterol, LDL, triglycerides, and HDLCalculated LDL -55.43 mg/dL and triglycerides -74.72 mg/dL, but explicitly noted inconsistency among studies and the need for higher-quality research.Key
Fogacci F et al. 2023Three-arm randomized double-blind placebo-controlled trial90Funding unknown; branded ingredient usedTotal cholesterol, LDL, non-HDL, triglycerides, and insulin resistanceReported 17.7% lower LDL and 16.6% lower triglycerides at 12 weeks in the high-dose group.Key
Spina A et al. 2024Randomized double-blind placebo-controlled trial64Sponsored by Bionap, which owns the data; company employee was a coauthorLDL, total cholesterol, HDL, oxidized LDL, and PON1After four months, LDL decreased 11.5% and total cholesterol 8.8%; the 5.5% HDL increase was a trend.Supportive
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-11).

Mollace V, Scicchitano M, Paone S, et al. Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo-Controlled Study. Endocr Metab Immune Disord Drug Targets. 2019;19(2):136-143. PMID: 30501605. DOI: 10.2174/1871530319666181203151513.
checked
Sadeghi-Dehsahraei H, Esmaeili Gouvarchin Ghaleh H, Mirnejad R, Parastouei K. The effect of bergamot (KoksalGarry) supplementation on lipid profiles: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(12):4409-4424. PMID: 36251526. DOI: 10.1002/ptr.7647.
checked
Fogacci F, Giovannini M, Imbalzano E, Cicero AFG. Metabolic and vascular effect of a new standardized bergamot phytocomplex: a three-arm, placebocontrolled, double-blind clinical trial. Arch Med Sci. 2023;19(5):1228-1235. PMID: 37732063. DOI: 10.5114/aoms/163368.
checked
Spina A, Amone F, Zaccaria V, et al. Citrus bergamia Extract, a Natural Approach for Cholesterol and Lipid Metabolism Management: A Randomized, Double-Blind Placebo-Controlled Clinical Trial. Foods. 2024;13(23):3883. PMID: 39682955. DOI: 10.3390/foods13233883.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Bergamot polyphenolic fraction x improvement in LDL and triglycerides Evidence Grade C card
[Chamgap] Bergamot polyphenolic fraction x improvement in LDL and triglycerides — Evidence Grade C·44. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/heart/bergamot-polyphenols-lipids/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.